{"id":834141,"date":"2025-04-04T16:19:45","date_gmt":"2025-04-04T20:19:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/"},"modified":"2025-04-04T16:19:45","modified_gmt":"2025-04-04T20:19:45","slug":"verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/","title":{"rendered":"Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, April  04, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cEHKvFoLRn56Tm4qHwywUMGdlsK79AA99CcWcHcJZ8zua4XrbSn7GOp2NqLy-n0BT5Kt-cFZQhAzsLviNBdo6hc_eL3GcbhT5Rv1EN3IHa8=\" rel=\"nofollow\" target=\"_blank\">Verve Therapeutics<\/a>, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on March 31, 2025, the company granted equity awards to three new employees, pursuant to the company\u2019s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p>The employees received stock options to purchase an aggregate of 50,700 shares of the company\u2019s common stock and an aggregate of 17,800 restricted stock units (RSUs). The options have an exercise price of $4.57 per share, which is equal to the closing price of the company\u2019s common stock on the date of grant. Each option has a 10-year term and will vest over a period of four years, with 25% of the shares vesting on the one-year anniversary of the grant date and the remainder vesting in equal monthly installments over the following three years, subject to each such employee\u2019s continued service with the company on each such vesting date. The RSUs will vest in equal annual installments on the first three anniversaries of April 1, 2025, subject to each such employee\u2019s continued service with the company on each such vesting date.<\/p>\n<p>\n        <strong>About Verve Therapeutics\u00a0<\/strong><br \/>\n        <br \/>Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The company\u2019s lead programs \u2013VERVE-102, VERVE-201, and VERVE-301 \u2013 target the three cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a). VERVE-102 is designed to permanently turn off the\u00a0<em>PCSK9<\/em>\u00a0gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the\u00a0<em>ANGPTL3<\/em>\u00a0gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia (HoFH). VERVE-301 is designed to permanently turn off the\u00a0<em>LPA<\/em>\u00a0gene to reduce Lp(a) levels. Lp(a) is a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=k6CqF0Pjb984chCNUV7DghaA7IjO5LEPAug_0c0fNEMALCHFyoDOVjiBAC96i9v-HaRtkVht5I6AahmDAkIEGs28lshTZOtOad58w6TMy70OQNqV6Fl4h8A-fgalGznZvFGxLAOQ7NvQGdJsEivnwvjFyz0I3ebOhkp3VUiZaOUYwNM611Lkw_wavWeC7td8PAkfxKatdVor91dzX73f6LbN_uBzuv35qs_5GWVxYHM=\" rel=\"nofollow\" target=\"_blank\">www.VerveTx.com<\/a>.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Jen Robinson<br \/>Verve Therapeutics, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ms0WT6JqxBoN06TXUCWYMT4uWcyYcZFfVfGu2RQSQQsN-ivxcjchLkjft8GRkqAlEBG4C8liuLDChRiQwm8VV21osudvZvC_nqgGMU_fqQ5DWleO1Ma4UPxWCTlVM3uAleB3WzkuO2zglEgn37wm-mKQ77VLRT-Th4sHQ3yBihS83cr27O16FW2f2m9ks7lx55TvT-NJZDSvG_59-_gsfn_zFHXyrSFRWKx8jTMo-EnZRUT7u0mRojI-P6ZouW-hEDO2LE8AAxOuxJRiyMQYEQ==\" rel=\"nofollow\" target=\"_blank\">jrobinson@vervetx.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Ashlea Kosikowski<br \/>1AB<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YqoO9yjXQsEb5WqzsffKDJ6pKuvThpKjbT7H1f-xTyInkIgaKugoE6n99ueCPX6xgciWFvzBb8LKs19-JAHWMRlkv_FDWuiCTT6EYU5HRdDV_O9cE01vpBfRJ0mq5tQN7cbUFw103l2aAXqqtxpr70lJreQ7My-v98WWWN48RfcinXX9GHH87x1S4_dGmj7hTSlbvvW5LcFJGxhCkl_lkqUQL19nK7KZ8ci5LabLKXYjPDaDKvEcJxOUHbaFXRlkaq_JVLhfaPD_YOcEqvlCSw==\" rel=\"nofollow\" target=\"_blank\">ashlea@1abmedia.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNjEwNCM2ODQ4ODU5IzIyMDM3MjA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MWI3MDFmM2MtZGJhOS00NTkyLWIzYjEtMmMyZmYxYTA1M2UyLTEyMTUyNzMtMjAyNS0wNC0wNC1lbg==\/tiny\/Verve-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, April 04, 2025 (GLOBE NEWSWIRE) &#8212; Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on March 31, 2025, the company granted equity awards to three new employees, pursuant to the company\u2019s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to purchase an aggregate of 50,700 shares of the company\u2019s common stock and an aggregate of 17,800 restricted stock units (RSUs). The options have an exercise price of $4.57 per share, which is equal to the closing price of the company\u2019s common stock on the date of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-834141","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, April 04, 2025 (GLOBE NEWSWIRE) &#8212; Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on March 31, 2025, the company granted equity awards to three new employees, pursuant to the company\u2019s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to purchase an aggregate of 50,700 shares of the company\u2019s common stock and an aggregate of 17,800 restricted stock units (RSUs). The options have an exercise price of $4.57 per share, which is equal to the closing price of the company\u2019s common stock on the date of &hellip; Continue reading &quot;Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-04T20:19:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNjEwNCM2ODQ4ODU5IzIyMDM3MjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2025-04-04T20:19:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\\\/\"},\"wordCount\":413,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNjEwNCM2ODQ4ODU5IzIyMDM3MjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\\\/\",\"name\":\"Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNjEwNCM2ODQ4ODU5IzIyMDM3MjA=\",\"datePublished\":\"2025-04-04T20:19:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNjEwNCM2ODQ4ODU5IzIyMDM3MjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNjEwNCM2ODQ4ODU5IzIyMDM3MjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/","og_locale":"en_US","og_type":"article","og_title":"Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"BOSTON, April 04, 2025 (GLOBE NEWSWIRE) &#8212; Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on March 31, 2025, the company granted equity awards to three new employees, pursuant to the company\u2019s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to purchase an aggregate of 50,700 shares of the company\u2019s common stock and an aggregate of 17,800 restricted stock units (RSUs). The options have an exercise price of $4.57 per share, which is equal to the closing price of the company\u2019s common stock on the date of &hellip; Continue reading \"Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-04T20:19:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNjEwNCM2ODQ4ODU5IzIyMDM3MjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2025-04-04T20:19:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/"},"wordCount":413,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNjEwNCM2ODQ4ODU5IzIyMDM3MjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/","name":"Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNjEwNCM2ODQ4ODU5IzIyMDM3MjA=","datePublished":"2025-04-04T20:19:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNjEwNCM2ODQ4ODU5IzIyMDM3MjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNjEwNCM2ODQ4ODU5IzIyMDM3MjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/834141","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=834141"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/834141\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=834141"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=834141"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=834141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}